top of page

Zantac Litigation: What You Need to Know About Ranitidine, NDMA, and Potential Cancer Claims

2 minutes ago
10 min read

Fact-Checked

This page has been researched, written, and reviewed in accordance with our editorial guidelines to ensure accuracy and relevance. This page has been reviewed and approved by Founding Partner, Tobias Licker. The last updated date reflects the most recent review of this content.

For many years, Zantac was a widely used medication for people experiencing heartburn, acid reflux, and other conditions caused by excess stomach acid. Available in both prescription and over-the-counter forms, the medication became a familiar name in households throughout the United States.


zantac
Zantac (ranitidine) and the NDMA contamination concerns behind the litigation.

However, concerns about a chemical impurity called N-Nitrosodimethylamine (NDMA) brought Zantac under regulatory scrutiny and eventually led to product liability lawsuits involving people who alleged that their use of ranitidine contributed to the development of cancer.


The controversy raised important questions about pharmaceutical safety, product testing, manufacturing practices, and the responsibilities of drug manufacturers.


If you or someone you know previously used Zantac and later received a cancer diagnosis, understanding the background of Zantac litigation may help you learn about the issues involved and the legal questions that could arise.


This guide explains what happened, why NDMA became a concern, which health conditions have been alleged in litigation, and what individuals should understand about potential legal claims.


What Is Zantac?


Zantac is a brand name associated with ranitidine, a medication classified as an H2 receptor antagonist or H2 blocker.


The medication works by reducing the amount of acid produced in the stomach. It was commonly prescribed or purchased over the counter to help maanger conditions such as:


  • Gastroesophageal reflux disease (GERD)

  • Frequent heartburn

  • Stomach ulcers

  • Duodenal ulcers

  • Conditions involving excessive stomach acid production


For many years, consumers relied on ranitidine for relief from recurring digestive and liquid formulations.


The medication was distributed in different forms, including tablets, capsules, and liquid formulations.


However, concerns emerged after laboratory testing identified NDMA in certain ranitidine products.


What Is NDMA and Why Did It Become a Concern?


NDMA stands for N-Nitrosodimethylamine, a chemical belonging to a group of compounds known as nitrosamines.


NDMA can occur in certain foods, drinking water, and environmental sources. It is also recognized as a probable human carcinogen, meaning that exposure may increase the risk of developing cancer.


The concern surrounding ranitidine was not simply that NDMA had been detected.


Researchers and regulators were particularly concerned about the possibility that NDMA levels in some ranitidine products could increase over time and under certain storage conditions.


According to the U.S. Food and Drug Administration (FDA), testing showed that NDMA levels in some ranitidine products increased as the medication aged and when exposed to temperatures above normal room conditions.


This raised concerns that consumers could be exposed to levels exceeding the FDA's acceptable daily intake limit.


The FDA established an acceptable daily intake limit of 96 nanograms per day for NDMA.


It is important to understand that exposure to NDMA does not automatically mean that an individual will develop cancer. The potential health effects depend on factors such as the amount and duration of exposure and other individual circumstances.


Why Was Zantac Withdrawn From the U.S. Market?


In September 2019, the FDA announced that it had become aware of laboratory testing identifying low levels of NDMA in ranitidine products.


As the investigation continued, the agency requested additional testing from manufacturers and evaluated whether the impurity could increase during storage.


On April 1, 2020, the FDA requested that manufacturers withdraw all prescription and over-the-counter ranitidine products from the U.S. market.


The decision followed testing indicating that NDMA levels could increase over time and under certain temperature conditions.


The FDA expressed concern that some products could expose consumers to unacceptable levels of NDMA.


This was a significant development because ranitidine had been widely used by consumers for many years.


The withdrawal also brought increased attention to the pharmaceutical companies involved in developing, manufacturing, distributing. and selling the medication.


What Is the Connection Between Zantac and Cancer?


The central issue in Zantac litigation involves allegations that NDMA exposure associated with ranitidine products contributed to the development of certain cancers.


NDMA has been classified as a probable human carcinogen, and research has examined its potential effects on human health.


However, the legal question is more specific.


Can the amount of NDMA associated with a person's use of ranitidine cause a particular type of cancer under the circumstances of that person's exposure?


This is known as the question of causation.


It is one of the most contested issues in Zantac litigation.


Plaintiffs in various lawsuits have alleged that long-term exposure to NDMA associated with ranitidine contributed their cancer diagnosis.


Manufacturers have disputed important aspects of these allegations, including the scientific evidence connecting the medication to the cancers claimed.


The distinction matters because a chemical's classification as a carcinogen does not, by itself, establish that a particular medication caused an individual's cancer.


Scientific evidence, exposure history, medical information, and applicable legal standards must all be considered.


What Cancers Have Been Alleged in Zantac Lawsuits?


Various Zantac lawsuits have involved individuals diagnosed with different types of cancer.


Conditions alleged in litigation have included:


  1. Bladder Cancer

Bladder cancer develops in the tissue of the bladder, the organ responsible for storing urine.


Some Zantac plaintiffs have alleged that their exposure to NDMA contributed to the development of bladder cancer.


  1. Stomach Cancer

Stomach cancer, also called gastric cancer, develops in the lining of the stomach.


Because ranitidine was commonly used to manager stomach-related conditions, some individuals who later received stomach cancer diagnoses have raised questions about their previous medication use.


  1. Colorectal Cancer

Colorectal cancer develops in the colon or rectum.


Some lawsuits have included allegations involving colorectal cancer and previous ranitidine exposure.


  1. Liver Cancer

The liver performs several important functions, including processing nutrients and filtering substances from the bloodstream.


Liver cancer has also appeared among the conditions alleged in Zantac-related litigation.


  1. Other Cancer Diagnoses

Other cancer types have also appeared in individuals lawsuits.


However, the inclusion of a particular diagnosis in litigation does not establish that Zantac caused that cancer.


The scientific evidence and legal requirements can differ depending on the diagnosis, exposure circumstances, and jurisdiction.


Individuals should not assume that a diagnosis alone establishes eligibility for compensation.


What Is Zantac Litigation About?


Zantac litigation generally involves product liability claims against companies alleged to have been responsible for manufacturing, marketing, distributing, or selling ranitidine products.


Plaintiffs have raised allegations involving several legal theories, including:


  • Failure to warn consumers about potential risks

  • Defective product design

  • Negligence in product development or testing

  • Inadequate safety evaluation

  • Failure to disclose relevant information about product stability

  • Other product liability allegations


These are allegations made in lawsuits, not findings that every defendant committed wrongdoing.


A central issue in these cases is whether the companies involved knew or should have known about potential risks associated with ranitidine and whether their conduct violated applicable legal duties.


The answer depends on the available evidence, the applicable law, and the specific claims being evaluated.


What Happened to the Zantac Lawsuits?


Zantac litigation became one of the most significant pharmaceutical product liability disputes in recent years.


Thousands of lawsuits were consolidated into federal multidistrict litigation (MDL No. 2924) in the Southern District of Florida.


An MDL allows federal cases involving common factual questions to be coordinated for certain pretrial proceedings. It does not mean that all claims become one lawsuit or that every plaintiff receives the same outcome.


The 2022 Federal Court Ruling


In December 2022, the federal district court excluded important expert testimony offered by plaintiffs concerning whether ranitidine could cause cancer.


The court concluded that the plaintiffs' general-causation experts had not provided sufficiently reliable scientific evidence under the applicable federal evidentiary standards.


The 2023 Summary Judgement


In May 2023, the federal court granted summary judgement in favor of defendants in the personal injury case within the MDL based on the exclusion of the plaintiffs' general-causation expert testimony.


The court subsequently entered final judgment in September 2023.


This was a significant setback for the plaintiffs involved in the federal proceedings.


Subsequent Apellate and State Court Developments


The federal MDL ruling became the subject of an appeal.


Zantac litigation also continued to involve separate state court proceedings, which have had their own procedural and evidentiary developments.


For example, the Delaware Supreme Court issued a decision in July 2025 addressing the admissibility of expert testimony in the state's separate Zantac Litigation.


However, subsequent Delaware proceedings also produced important rulings unfavorable to plaintiffs. In January and April 2026, the Delaware Superior Court issued decisions addressing statute-of-limitations and summary-judgement issues.


These developments demonstrate why it is important to evaluate the status of a Zantac claim based on the particular court, jurisdiction, and legal circumstances rather than assume that every lawsuit is proceeding under the same rules.


Is Zantac Available Again?


An important recent development is that ranitidine returned to the U.S. market in a reformulated version.


On November 24, 2025, the FDA announced its approval of reformulated ranitidine tablets following a safety review and manufacturing changes intended to address the previous NDMA impurity concerns.


The new formulation includes updated storage and handling instructions.


This development does not erase the historical concerns involving earlier ranitidine formulations, nor does it establish that the older products caused cancer.


It is important to distinguish between the previously marketed formulations involved in historical litigation and the newly approved reformulated medication.


Consumers currently taking medication should consult their healthcare providers about appropriate treatment and should follow the FDA's current product-specific guidance.


Who May Have a Potential Zantac-Related Legal Claim?


Individuals who previously used ranitidine and later developed certain medical conditions may have questions about whether they have legal options.


However, previous use of Zantac alone does not establish a valid product liability claim.


An attorney evaluating a potential case may need to consider several factors.


Previous Ranitidine Use


Information about the medication is important.


Relevant details may include:


  • Whether the individual used brand-name Zantac or generic ranitidine

  • Approximately when the medication was used

  • How frequently it was taken

  • How long the medication was used

  • Whether the medication was prescribed or purchased over the counter


Prescription records, pharmacy receipts, medical records, and other available documentation may help establish a history of use.


Medical Diagnosis


The individual's medical history and diagnosis are also important.


An attorney may need to review medical records, pathology reports, treatment history and other documentation relevant to the diagnosed condition.


The type of cancer involved can affect the scientific and legal questions that must be evaluated.


Exposure History


The circumstances surrounding medication use also may also matter.


This can include the duration of use, approximate dosage, product identification, and any available information about storage conditions.


Not e very individual will have complete records, but available documentation can help an attorney understand the circumstances of a potential claim.


Applicable Legal Deadlines


Time limits for filing product liability claims vary depending on the applicable state law and circumstances of the case.


These deadlines may involve questions about when an injury was discovered, when a person reasonably should have connected an injury to a potential cause, and other legally relevant facts.


Waiting too long to seek legal guidance may affect an individual's ability to pursue a claim.


Anyone considering a potential claim should have the applicable deadlines evaluated promptly by an attorney.


What Should You Do If You Previously Used Zantac?


If you previously used Zantac or another product and have concerns about a later cancer diagnosis, consider taking the following steps.


  1. Gather available medication records


Look for prescription records, pharmacy receipts, medication bottles, or other documents that may help establish previous ranitidine use.


  1. Organize your medical records


Keep copies of diagnosis report, pathology results, treatment results, treatment records, and relevant medical documentation.


  1. Write down your medication history


Record approximately when you started and stopped taking ranitidine , how frequently you used it, and whether it was prescription or over-the-counter medication.


  1. Continue working with your healthcare provider


Medical decisions should be made with qualified healthcare professionals. Do not change or discontinue treatment based solely on information found online.


5. Seek legal guidance


A qualified attorney can review the available information, explain applicable legal requirements, and determine whether further investigation may be appropriate.


Understanding Your Legal Options


Pharmaceutical product liability cases can involve complicated scientific evidence, medical records, regulatory decisions, and legal requirements.


The history of Zantac litigation demonstrates that a product safety concern does not automatically establish liability or guarantee compensation. each potential claim must be evaluated based on its individual based on its individual facts and applicable law.


If you have questions about a potential pharmaceutical or product liability matter, understanding your legal options is an important first step.


A & L, Licker Law Firm, LLC serves clients in Missouri and Illinois. Our firm encourages individuals with legal questions to seek appropriate guidance about their circumstances and available options.


To learn more about the firm's legal services, visit lickerlawfirm.com or call (636) 916-5400.


Frequently Asked Questions About Zantac Litigation


Does taking Zantac mean I will develop cancer?


No. Previous use of Zantac does not mean that an individual will develop cancer. The potential effects of NDMA exposure depend on multiple factors, and a person's medical condition cannot be attributed to a medication based on exposure history alone.


Was Zantac recalled by the FDA?


On April 1, 2020, the FDA requested that manufacturers withdraw all prescription and over-the-counter ranitidine products from the U.S market because of concerns about NDMA levels increasing over time and under certain storage conditions.


Is ranitidine available in the United States again?


Yes. On November 24, 2025, the FDA announced approval of reformulated ranitidine tablets following a safety review and manufacturing changes intended to address previous NDMA impurity concerns.


What cancers have been associated with Zantac lawsuits?


Lawsuits have included allegations involving bladder, stomach, colorectal, liver, and other cancers. However, allegations in litigation do not establish that ranitidine caused any particular cancer.


Can I still file a Zantac lawsuit?


Whether an individual can pursue a claim depends on the facts, applicable state law, procedural history. scientific evidence, and filing deadlines. Previous medication use alone does not establish eligibility. An attorney must evaluate the specific circumstances.


What documents might be useful when discussing a potential claim?


Potentially useful documents include prescription records, pharmacy receipts, medication packaging, medical records, pathology reports, diagnosis information, and treatment records.


References

The following government and court resources provide additional information about ranitidine, NDMA, and Zantac-related litigation.


  1. U.S. Food and Drug Administration (FDA). FDA Requests Removal of All Ranitidine Products (Zantac) from the Market – April 1, 2020.

  2. U.S. Food and Drug Administration (FDA). Questions and Answers: NDMA Impurities in Ranitidine (Commonly Known as Zantac).

  3. U.S. Food and Drug Administration (FDA). Laboratory Tests: Ranitidine.

  4. U.S. Food and Drug Administration (FDA). FDA Approves Reformulated Ranitidine Following Comprehensive Safety Review – November 24, 2025.

  5. U.S. District Court for the Southern District of Florida. In re: Zantac (Ranitidine) Products Liability Litigation, MDL No. 2924.

  6. Delaware Supreme Court. In re Zantac (Ranitidine) Litigation, No. 255, 2024 – July 10, 2025.

  7. Delaware Superior Court. In re Zantac (Ranitidine) Litigation – Opinion and Order on Defendants' Motion for Summary Judgment, April 14, 2026.


DISCLAIMER: This article is for informational purposes only and does not constitute legal advice. Reading this article does not create an attorney-client relationship. Laws change regularly and the application of any rule depends on the specific facts of each case. For guidance regarding your specific situation, please contact A & L, Licker Law Firm, LLC directly.

 
 
 

Comments


bottom of page